2016
DOI: 10.15511/ejcm.16.00231
|View full text |Cite
|
Sign up to set email alerts
|

Hypertrophic obstructive cardiomyopathy and the cost of treatment

Abstract: Objective: To evaluate the demographics of patients admitted with Hypertrophic Obstructive Cardio-Myopathy (HOCM) and the financial burden of this disease on the health care system. Methods:The Healthcare Cost and Utilization Project (HCUP), sponsored by The Agency for Healthcare Research and Quality's (AHRQ), includes the largest collection of longitudinal hospital care data in the United States of America. HCUP creates the National In-patient Sample data (NIS) to help conduct national and regional analyses o… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
4
0

Year Published

2021
2021
2023
2023

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(4 citation statements)
references
References 5 publications
0
4
0
Order By: Relevance
“…Although several previous studies have examined costs for specific episodes of care, to our knowledge, this is the first study to examine the longitudinal costs of unselected patients with oHCM. In a previous population-based study of patients with oHCM, Jan and colleagues used data from the National Inpatient Sample to assess inpatient costs for 2,605 patients who were hospitalized with a principal diagnosis of oHCM in 2013 [16]. They found a mean length of stay of 4.9 days and mean cost/admission of $25,433-results for length of stay that were similar to those for patients who were hospitalized in our study (5.5 days).…”
Section: Comparison With Previous Studiesmentioning
confidence: 99%
See 1 more Smart Citation
“…Although several previous studies have examined costs for specific episodes of care, to our knowledge, this is the first study to examine the longitudinal costs of unselected patients with oHCM. In a previous population-based study of patients with oHCM, Jan and colleagues used data from the National Inpatient Sample to assess inpatient costs for 2,605 patients who were hospitalized with a principal diagnosis of oHCM in 2013 [16]. They found a mean length of stay of 4.9 days and mean cost/admission of $25,433-results for length of stay that were similar to those for patients who were hospitalized in our study (5.5 days).…”
Section: Comparison With Previous Studiesmentioning
confidence: 99%
“…An important first step in this line of investigation is to understand the clinical and economic burden of oHCM on both patients and the healthcare system. Although there have been several small studies of healthcare resource utilization (HRU) and costs in patients with HCM, these have generally focused on individuals undergoing invasive therapies, and there have been no longitudinal studies among unselected patients [14][15][16]. Moreover, there have been no studies quantifying the clinical and economic burden of patients with obstructive HCM, or the subgroups of patients with asymptomatic or symptomatic oHCM.…”
Section: Introductionmentioning
confidence: 99%
“…This might be subjective and may sometimes be based on estimations. However, previous cost-of-illness studies used aggregated databases and thus neglected important information about broader costs such as patient and family costs, productivity losses and costs beyond healthcare, which are included in this study [10][11][12]. Secondly, the to-be-used questionnaires are validated for an adult population only, hence minors will be excluded [20].…”
Section: Discussionmentioning
confidence: 99%
“…1 The structured timeline of the study per subject. QoL quality of life, EQ-5D-5L EuroQol questionnaire, KCCQ Kansas City cardiomyopathy questionnaire, iMCQ medical consumption questionnaire, iPCQ productivity cost questionnaire about broader cost types [10][11][12]. Furthermore, QoL studies are rare and none have measured QoL with the EQ-5D-5L, the required instrument according to Dutch guidelines [5,[13][14][15].…”
Section: Subject Follow-up Finalisationmentioning
confidence: 99%